Which Is The Best Investment For You? High Yield Pfizer or Higher Growth Merck?

Which Is The Best Investment For You? High Yield Pfizer or Higher Growth Merck? | FAST Graphs

Рет қаралды 13,183

Күн бұрын

Which is the best investment for you!
If you are interested in investing in a high quality large pharmaceutical company, two of your primary choices would be Pfizer (PFE) or Merck (MRK), of course, Merck being the largest. Which one of these investments would suit you better as an investor?
In this video, Chuck Carnevale, Co-founder of FAST Graphs, a.k.a. Mr. Valuation is going to answer that question - it depends on what your goals, objectives and risk tolerances are.
Time Codes:
0:00 - Introduction by Chuck Carnevale
0:48 - Pfizer (PFE)
10:10 - Merck & Co (MRK)
Introducing The FAST Graphs’ Affiliate Program! Earn money and help other investors by introducing them to the most powerful fundamental analyzer software tool available. Help others become smarter and more profitable investors.
fastgraphs.com/fast-graphs-af...
Disclaimer: FAST Graphs is a tool designed to reveal and present information related to financial data and investment metrics. It is not intended to provide specific advice or recommendations. Instead, it offers a comprehensive view of relevant data, empowering users to make informed decisions based on their own analysis. It's your first step to a more comprehensive research and due diligence process. In short, it is a tool to think with. The opinions in this video are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned.
Sign up for your 7-day free trial:
www.fastgraphs.com
SUBSCRIBE To Our KZfaq Channel
#investing #merck #pfizer

Пікірлер: 68

@aritraray3068 20 күн бұрын

An update on Bristol Myers would be great. Thanks.

@100Mario81 20 күн бұрын

I got in on PFE at 30 by selling puts so my cost basis is 27 and selling calls on it to lower it. I would like to see a video on BMY if possible, thank you.

@MarshaBonForte 21 күн бұрын

Great presentation as always. I bought Pfizer at $25 and change so I’m already up. It seemed like a no brainer. It is still a good buy.

@XbhSrs 5 күн бұрын

*Excellent! I really do have a question. For someone with less than $17,000 to trade or above. How would you recommend we enter into trading as a newbie? I am looking at trading with professional trader and copying their strategies rather than trading myself. I would greatly appreciate any suggestions*

@Michael68689 5 күн бұрын

I would suggest to reach out to Mavis. What impresses me most about Mavis is how well she accumulate profit for client's and explains basic concept of winning before actually trading for you. And letting you use her trade signals. And she will also teach you how to trade as she trade for you, and let you know when to enter and exit trade for maximum profit as she trade for you. This goes a long way to ensure winning trades.

@XbhSrs 5 күн бұрын

Please I'm a beginner, where can someone willing to start up trading reach Mavis?

@Michael68689 5 күн бұрын

She's mostly attend to client's faster on Telegrams, using the user name.

@Michael68689 5 күн бұрын

*Mavis131大大大 ...that's it*

@Anastasia349 5 күн бұрын

I'm shocked that Mavis name was mentioned and recommended. I learn and earn through her analysis. Which I always speaks volumes about her and also recommend people to her

@menlubruce580 20 күн бұрын

thanks Chuck, I too would like an update on BMY as well.

@topinvest4385 11 күн бұрын

What is about Bristol-Myers Squibb? Can you maybe give us an Update? Greetings from Germany :)

@iangantner6976 20 күн бұрын

Thumbs up. Recently started acquiring Pfizer. Not sure what makes me more excited- Pfizer having spent quite a bit on cancer related acquisitions or the potential yield on cost increases. Either way, I feel like it’s a win. If any of my dollars help cancer patients, I’m happy. If I make money I’m happy.. win/win!

@wmartin 21 күн бұрын

Thanks Chuck!

@photomanual01 21 күн бұрын

Great stuff as always! Any thoughts on Whirlpool? I enjoyed your video years ago, "let's take it for a whirl" if memory serves...

@Felcity 20 күн бұрын

Thank you very very much for this kind of content - for free!

@kevinmendoza4402 20 күн бұрын

I’m buying both! 🚀🤑💎👐

@janoz06 21 күн бұрын

Excellent video thanks

@hahaman5255 18 күн бұрын

Can you do Bmy analysis sir?

@_VlCTOR_ 20 күн бұрын

what is the problem with BMY?

@FASTgraphs 20 күн бұрын

Patent cliff with new blockbuster drugs coming slowly. Dividend appears safe. Long term play requiring patience. www.bms.com/assets/bms/us/en-us/pdf/investor-info/boa-global-healthcare-conference-20224-transcript.pdf

@rolf5282 20 күн бұрын

Yes as always great information thank's from europe

@martinithechobit 15 күн бұрын

Ty boss as my experience in the pharmacy these are big names. But handful of big boys out there as well.

@dieterfrommunich758 6 күн бұрын

thank you

@marcojansen9599 19 күн бұрын

With Pharma it is always difficult to convert pipeline to future (3-8 years) growth numbers for outsiders.

@FASTgraphs 19 күн бұрын

I start by looking at the projections of the leading analysts following the stock. In addition to their own work they also are given guidance by the companies themselves. Furthermore, this is where the analyst scorecard comes in. Regards, Chuck

@donkemp8151 13 күн бұрын

Bought Merck at $82. I think I’ll hold for a bit longer.

@user-vm6ck7lt6v 21 күн бұрын

Is CHWY a good growth stock?

@felipelorenzodellalucia1245 20 күн бұрын

Hi Chuck, how come a negative growth stock should be valued at a 15 PE and a 2% positive growth valued as 13 PE? It doesn't make sense. Shouldn't the negative growth be somewhat truncated at the 13 PE?

@FASTgraphs 19 күн бұрын

Because valuation is only part of the equation and represents soundness. Rate of return is a function of the future growth or lack thereof. In other words the negative grower is a bad investment in any valuation. To repeat, valuation is a measurement of soundness not rate of return. Here is an article I wrote discussing it in more detail: fastgraphs.com/blog/valuation-is-a-measurement-of-soundness-and-not-the-primary-total-return-producer-part-1/ regards, Chuck

@felipelorenzodellalucia1245 19 күн бұрын

Thanks for the clarification, Chuck!

@Gee60711 20 күн бұрын

I sold both and increased my investment in the S&P 500. ETFs are the best way to achieve peace of mind to a certain extent.

@FASTgraphs 19 күн бұрын

The S&P 500 is at an all-time high. Furthermore, it is a market of stocks and not a stock market which implies that their overvalued undervalued and fairly valued stocks within the index. Common sense should indicate that buying attractively valued stocks would outperform the S&P 500 over the long run when the S&P 500 is this overvalued. In short this is the worst time to be investing in the index. The cardinal rule of investing is buy low and sell high not the other way around. Just trying to be helpful. Chuck

@ahsugoi 19 күн бұрын

@@FASTgraphshave you considered that the S&P may be at an all time high because of a substantial increase in the money supply? You've been saying this for what seems like a while now. It may be a new normal that you need to adjust to rather than clinging to an old valuation framework.

@FASTgraphs 19 күн бұрын

@@ahsugoi this is been the longest bull market in history and all bull markets end with a bear market. And valuation is always relevant and cannot go out of date the principles of business, economics, and accounting are timeless. Valuation matters and it matters a lot. And all that macroeconomic nonsense is just that macroeconomic nonsense. Price is what you pay and value is what you get. I was trying to be helpful but go ahead continue to be a genius in a bull market. Regards, Chuck

@ahsugoi 19 күн бұрын

@@FASTgraphs there will no doubt be another bear market. I'm just offering another take on what you continually insist is persistent overvaluation. If there's a lot more money in circulation, what do you think that will do to asset prices? Valuation is relative. If everything (the market and other assets) is overvalued, is it overvaluation or might it be repricing due to an increase in the money supply?

@FASTgraphs 19 күн бұрын

@@ahsugoi Do you understand earning yield?

@bonanzatime 12 күн бұрын

I'm all in with the rapper, Merky Merk Merk😎

@kelleyhaldorson209 17 күн бұрын

I have decided to ETF my pharmaceuticals. I can't follow the pipeline info, it is out of my realm of competence by far!

@davebean2886 21 күн бұрын

Comparison to BMY which was looked at a year ago? kzfaq.info/get/bejne/b7iBpcJ6vK_XYZs.html

@tyrabjurman3584 18 күн бұрын

7 Oct 2022, more like almost two years ago.

@Buffetology 20 күн бұрын

Can you please stop giving away the secret sauce ! Wish I found you decades earlier

@pearlperlitavenegas2023 21 күн бұрын

2nd!

@JakeandAnnie 21 күн бұрын

What about Pfizer's spin off Viatris?

@FASTgraphs 21 күн бұрын

what about Mercks spinn-off Organon. My point is that they are separate companies not relevant to this video.

@lolman456 21 күн бұрын

1st

@Prachka1 21 күн бұрын

Any pharmaceutical company that profits from not developing actual cures and only develops dependency drugs - deserves $0 of my dollars and that is what they are getting.

@derf2170 21 күн бұрын

Until you get sick and need medicine

@Prachka1 21 күн бұрын

@@derf2170 read above post

@Prachka1 21 күн бұрын

@@derf2170 read above comment

@Prachka1 21 күн бұрын

@@derf2170 , again - read, key word here, above comment.

@Prachka1 21 күн бұрын

@@derf2170 medicine - not drug.